-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Raises Price Target to $20

Benzinga·12/18/2024 16:32:16
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and raises the price target from $3 to $20.